← Browse by Condition
Medical Condition
newly diagnosed glioblastoma
Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2, Phase 3, Phase 2
ClinicalMetric tracks all active clinical trials for newly diagnosed glioblastoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — newly diagnosed glioblastoma Clinical Trials
How many clinical trials are currently recruiting for newly diagnosed glioblastoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for newly diagnosed glioblastoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for newly diagnosed glioblastoma?
newly diagnosed glioblastoma research spans Phase 1 (2 trials), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a newly diagnosed glioblastoma clinical trial?
Eligibility criteria for newly diagnosed glioblastoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 2
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT07346144 Phase 1, Phase 2
Recruiting
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
Enrollment
68 pts
Location
United States, Unite...
Sponsor
Trogenix ltd
NCT07021339 Phase 3
Recruiting
Anterior Temporal Lobectomy in Temporal Glioblastoma
Enrollment
178 pts
Location
Germany
Sponsor
University Hospital, Bonn
NCT07326566 Phase 2
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Enrollment
162 pts
Location
United States
Sponsor
Black Diamond Therapeutics, In...
NCT05380349 EARLY_Phase 1
Recruiting
Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma
Enrollment
10 pts
Location
United States
Sponsor
Swedish Medical Center
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology